Athira Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announced its participation in two upcoming investor conferences: the JMP Securities Life Sciences Conference on June 17, 2021, at 3:30 PM ET and the Raymond James Human Health Innovation Conference on June 21, 2021, at 1:20 PM ET. Management will engage in discussions about neurodegenerative diseases, focusing on new therapeutic targets for conditions like Alzheimer’s and Parkinson’s. Webcasts of the presentations will be available on the company’s website for 30 days post-event.

–   JMP Securities Life Sciences Conference

–   Raymond James Human Health Innovation Conference

BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira“), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that company management will participate in the following upcoming investor conferences:

•		JMP Securities Life Sciences Conference
		Format: Fireside chat
		Date: Thursday, June 17, 2021
		Time: 3:30 PM ET
•		Raymond James Human Health Innovation Conference
		Panel Topic: Neurodegenerative Diseases: New & Improved Therapeutic Targets for Alzheimer's & Parkinson's Disease
		Participant: Mark Litton, Ph.D., MBA, Chief Operating Officer
		Date: Monday, June 21, 2021
		Time: 1:20 PM ET

A live webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for at least 30 days following the event.

For more detail and to register for the events above, please visit https://investors.athira.com/news-and-events/events-and-presentations

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Julie.rathbun@athira.com
206-769-9219

FAQ

What is the date and time of Athira Pharma's presentation at the JMP Securities Life Sciences Conference?

Athira Pharma will present at the JMP Securities Life Sciences Conference on June 17, 2021, at 3:30 PM ET.

What topic will Athira Pharma discuss at the Raymond James Human Health Innovation Conference?

Athira Pharma will discuss neurodegenerative diseases, particularly new therapeutic targets for Alzheimer's and Parkinson's diseases.

Who will represent Athira Pharma at the Raymond James Human Health Innovation Conference?

Mark Litton, Ph.D., MBA, Chief Operating Officer, will represent Athira Pharma at the conference.

How can I access the presentations from Athira Pharma's upcoming conferences?

Live webcasts of the presentations can be accessed from the Investors section of Athira's website.

When will the archived replay of Athira Pharma's conference presentations be available?

The archived replay will be available for at least 30 days following each event.